Latest News
NCCN Clinical Practice Guidelines in Oncology Update Recommends BESREMi® for the Treatment of Polycythemia Vera

Source: Pharma Essentia

Reflecting its strong clinical profile and broad label, NCCN Guidelines include BESREMi as an option for PV regardless of treatment history, and for use in both low- and high-risk settings

PharmaEssentia USA Corporation, the U.S. subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) has been updated to include BESREMi® (ropeginterferon alfa-2b-njft) as a recommended therapeutic option for the treatment of adults with polycythemia vera (PV).

The NCCN is a highly renowned and respected not-for-profit alliance of leading cancer centers in the United States. Its treatment practice guidelines are widely respected and followed by the U.S. physician community, and serve to inform and facilitate coverage decisions with payers for oncology therapies. Consistent with the broad indication for BESREMi upon its U.S. regulatory approval in November 2021, the guidelines provide consideration for use of the treatment among both high-risk and low-risk adult patients, regardless of their treatment history.

“Importantly, the NCCN Guidelines update includes mention of BESREMi in multiple settings, and in particular, as the only systemic option for low-risk patients with PV, which signals a shift toward more proactive treatment earlier in the disease journey,” said Ruben Mesa, M.D., FACP, Executive Director of the UT Health San Antonio MD Anderson Cancer Center. “Now, treating physicians can leverage these expert guidelines to gain greater familiarity with BESREMi in the real world setting and understand its broad utility for patient care in a variety of treatment settings.”

“Our goal with BESREMi has been to offer a compelling therapeutic alternative to conventional treatment options that can enable physicians to gain durable control over the disease beyond the symptoms and help more patients reach their long-term health goals,” said Raymond Urbanski, M.D., Ph.D., U.S. Head of Clinical Development and Medical Affairs. “The NCCN Guidelines update just three months following our approval illustrates the community’s recognition of the strong potential of BESREMi in PV care.”

More information:

Information appearing on this website (images and texts, unless otherwise indicated) is the property of IBMI. To use or share, please indicate the source.
©Institute for Biotechnology and Medicine Industry (IBMI) All rights reserved.
Address:16F.-1, No.3, Park St., Nangang Dist., Taipei City 115, Taiwan (R.O.C.) Contact Number:(02)2655-8168 Fax:(02)2655-7978